Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Retained Earnings: 2016-2025

Historic Retained Earnings for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to -$4.4 billion.

  • Ultragenyx Pharmaceutical's Retained Earnings fell 15.17% to -$4.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.4 billion, marking a year-over-year decrease of 15.17%. This contributed to the annual value of -$4.0 billion for FY2024, which is 16.80% down from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Retained Earnings is -$4.4 billion, which was down 4.27% from -$4.2 billion recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Retained Earnings high stood at -$1.8 billion for Q1 2021, and its period low was -$4.4 billion during Q3 2025.
  • Over the past 3 years, Ultragenyx Pharmaceutical's median Retained Earnings value was -$3.7 billion (recorded in 2024), while the average stood at -$3.7 billion.
  • Data for Ultragenyx Pharmaceutical's Retained Earnings shows a maximum YoY crashed of 34.75% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Retained Earnings stood at -$2.1 billion in 2021, then tumbled by 34.12% to -$2.8 billion in 2022, then declined by 21.81% to -$3.4 billion in 2023, then fell by 16.80% to -$4.0 billion in 2024, then decreased by 15.17% to -$4.4 billion in 2025.
  • Its Retained Earnings was -$4.4 billion in Q3 2025, compared to -$4.2 billion in Q2 2025 and -$4.1 billion in Q1 2025.